Comparative effectiveness

Relevant publications

1. O. Alagoz, F. P. May, C.A. Doubeni, A.M. Fendrick, V. Vahdat, C. Estes, T. Ellis, P.J. Limburg, D. Brooks (2024),”Impact of racial disparities in follow-up and quality of colonoscopy on colorectal cancer outcomes,” Journal of the National Cancer Institute, published online on 24 Jul 2024, https://doi.org/10.1093/jnci/djae140.

2. N.K. Stout, D.L. Miglioretti, Y. Su, C.I. Lee, L. Abraham, O. Alagoz, et al. (2024) “Breast cancer screening using mammography, digital breast tomosynthesis and MRI by breast density: A model-based comparative effectiveness analysis,” JAMA Internal Medicine,  published online August 26, 2024. https://doi:10.1001/jamainternmed.2024.4224.

3. A. Trentham-Dietz, …., O. Alagoz, C.B. Schechter, N.K. Stout, D.L. Miglioretti, J.S Mandelblatt (2024), “Collaborative modeling to compare different breast cancer screening strategies: a decision analysis for the US Preventive Services Task Force,” JAMA, 331(22): 1947-1960.

4. J.L. Caswell-Jin, L.P. Sun, D. Munoz, Y. Lu, Y. Li, H. Huang, J.M. Hampton, J. Song, J. Jayasekera, C. Schechter, O. Alagoz, N.K. Stout, A. Trentham-Dietz, S.J. Lee, X. Huang, J.M. Mandelblatt, D. Berry, A.W. Kurian, S.K. Plevritis (2024), “Analysis of Breast Cancer Mortality in the United States: 1975 to 2019,” JAMA, 331 (3), 233-241.

5. K.P. Lowry, H.A. Geuzinge, N.K. Stout, O. Alagoz, et al. (2022), “Breast Cancer Screening Strategies in Women with ATM, CHEK2, and PALB2 Pathogenic Variants: A Comparative Modeling Analysis,” JAMA Oncology, 8(4):587-596.

6. J.M. Yeh, K.P. Lowry, C.B. Schechter, L.R. Diller, G. O’Brien, O. Alagoz, et al. (2022), “Breast Cancer Screening Among Childhood Cancer Survivors Treated Without Chest Radiation: Clinical Benefits and Cost-Effectiveness,” Journal of the National Cancer Institute, 114(2):235–244.

7. O. Alagoz, A.K. Sethi, B.W. Patterson, M. Churpek, G. Alhanaee*, E. Scaria*, N. Safdar, (2021), “The Impact of Vaccination to Control COVID-19 Burden in the United States: A Simulation Modeling Approach,” PLoS ONE, 16(7):e0254456.

8. O. Alagoz, K.P. Lowry, A.W. Kurian, J. Mandelblatt, M.A. Ergun*, H. Huang, S.J. Lee, C.B. Schechter, A.N.A. Tosteson, D.L. Miglioretti, A. Trentham-Dietz, S.J. Nyante, K. Kerlikowske, B.L. Sprague, N.K. Stout (2021), “Impact of the COVID-19 Pandemic on Breast Cancer Mortality in the US: Estimates from Collaborative Simulation Modeling,” Journal of the National Cancer Institute, 113(11):1484–1494.

9. E. Zwick*, C. S. Pepperell, O. Alagoz (2021), “Representing Tuberculosis Transmission with Complex Contagion: An Agent-Based Simulation Modeling Approach,” Medical Decision Making, 41(6):641-652.

10. E. Scaria*, A. Barker*, O. Alagoz, N. Safdar, (2021), “Association of Visitor Contact Precautions With Estimated Hospital-Onset Clostridioides difficile Infection Rates in Acute Care Hospitals,” JAMA Network Open, 4(2): e210361.

11. N.T. van Ravesteyn, C.B. Schechter, J.M. Hampton, O. Alagoz, J.J. van den Broek, K. Kerlikowske, J. Mandelblatt, D.L. Miglioretti, B.L. Sprague, N.K. Stout,  H.J. de Koning, A. Trentham-Dietz,  A.N.A. Tosteson (2021), “Trade-offs between harms and benefits of different breast cancer screening intervals among low-risk women,” Journal of the National Cancer Institute, 113(8):1017–1026.

12. N. Mukhtarova, O. Alagoz, Y. Chen*, K. Hoppe (2021), “Evaluation of different blood pressure assessment strategies and cutoff values to predict postpartum hypertension-related readmissions: A retrospective cohort study,” AJOG Maternal Fetal Medicine, 3(1):100252.

13. O. Alagoz, A.K. Sethi, B.W. Patterson, M. Churpek, N. Safdar, (2021), “Effect of Timing of and Adherence to Social Distancing Measures on COVID-19 Burden in the United States: A Simulation Modeling Approach,” Annals of Internal Medicine, 174(1):50-57.

14. J.M. Yeh, K.P. Lowry, C.B. Schechter, L.R. Diller, O. Alagoz, G.T. Armstrong, J.M. Hampton, W. Leisenring, Q. Liu, J.S. Mandelblatt, D.L. Miglioretti, C.S. Moskowitz, K.C. Oeffinger, A. Trentham-Dietz, N.K. Stout (2020), “Clinical benefits, harms and cost-effectiveness of breast cancer screening for survivors of childhood cancer treated with chest radiation: A comparative modeling study,” Annals of Internal Medicine, 173(5):331-341.

15. A.K. Barker*, E. Scaria*, O. Alagoz, A. Sethi, N. Safdar (2020), “Reducing C. difficile in Children: An agent-based modeling approach to evaluate intervention effectiveness,” Infection Control & Hospital Epidemiology, 41(5):522-530.

16. K.P. Lowry, A. Trentham-Dietz, C.B. Schechter, O. Alagoz, W.E. Barlow, E.S. Burnside, E.F. Conant, J.M. Hampton, H. Huang, K. Kerlikowske, S.J. Lee, D.L. Miglioretti, B.L. Sprague, A.N.A. Tosteson, M. Yaffe, N.K. Stout (2019), “Long-term Outcomes and Cost-effectiveness of Breast Cancer Screening with Digital Breast Tomosynthesis in the United States,” Journal of the National Cancer Institute, 112(6):582-589.

17. O. Alagoz, A. Hajjar*, S. Chootipongchaivat, N.T. van Ravesteyn, J. Yeh, M.A. Ergun*, H.J. de Koning, B. Chicoine, B. Martin (2019), “Benefits and Harms of Mammography Screening for Women with Down Syndrome,” Journal of General Internal Medicine, 34(11):2374-2381.

18. E.S. Burnside, A. Trentham-Dietz, C.M. Shafer, J.M. Hampton, O. Alagoz, J.R. Cox, E. Mischo, S.B. Schrager, L.G. Wilke (2019), “Age-Based Versus Risk-Based Mammography Screening in Women 40-49 Years Old: a Cross Sectional Study,” Radiology, 292(2):321-328.

19. M.J. Yaffe, N. Mittmann, O. Alagoz, A. Trentham-Dietz, A.T.A. Tosteson, N.K. Stout (2018), “The Effect of Mammography Screening Regimen on Incidence-based Breast Cancer Mortality,” Journal of Medical Screening, 25(4):197-204.

20. S. Plevritis, D. Munoz, A. Kurian, N.K. Stout, O. Alagoz, A. Near, S.J. Lee, J. van den Broek, X. Huang, C. Schechter, B. Sprague, H. de Koning, A. Trentham-Dietz, N.T. van Ravesteyn, Y. Chang, Y. Lin, M. Ergun*, H. Huang, D. Berry, J. Mandelblatt (2018), “Associations of Screening and Treatment with Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012,” Journal of American Medical Association (JAMA), 319(2):154-164.

21. A. Trentham-Dietz, M.A. Ergun*, O. Alagoz, N.K. Stout, R.E. Gangnon, J.M. Hampton, K. Dittus, T.A. James:M. Vacek, S.D. Herschorn, E.S. Burnside, A.N.A. Tosteson, D.L. Weaver, B.L. Sprague (2018), “Comparative Effectiveness of Incorporating a Hypothetical DCIS Prognostic Marker into Breast Cancer Screening,”  Breast Cancer Research and Treatment, 168(1):229-239.

22. C.M. Rutter, J.J. Kim, R.G.S. Meester, B.L. Sprague, E.A. Burger, A.G. Zauber, M. Ergun*, N.G. Campos, C.A. Doubeni, A. Trentham-Dietz, S. Sy, O. Alagoz, N.K. Stout, I. Lansdorp-Vogelaar, D.A. Corley, A.N.A. Tosteson (2018), “Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study,” Cancer Epidemiology, Biomarkers & Prevention, 27(2):158-164.

23. A. Barker*, O. Alagoz, N.Safdar (2018), “Interventions to reduce the incidence of hospital-onset Clostridium difficile infection: An agent-based modeling approach to evaluate clinical effectiveness in adult acute care hospitals,” Clinical Infectious Diseases, 66(8):1192-1203.

24. A. Trentham-Dietz, K. Kerlikowske, N.K. Stout, D.L. Miglioretti, C.B. Schechter, M.A. Ergun*, J.J. van den Broek, O. Alagoz, B.L. Sprague, N.T. van Ravesteyn, A.M. Near, R.E. Gangnon, J.M. Hampton, Y. Chang, H.J. de Koning, J.S. Mandelblatt, A.N.A. Tosteson (2016), “Tailoring Breast Cancer Screening Intervals by Breast Density and Risk for Women Aged 50 Years or Older: Collaborative Modeling of Screening Outcomes,” Annals of Internal Medicine, 165(10):700-712.

25. J.S. Mandelblatt, N.K. Stout, C.B. Schechter, J.J. den Broek, D.L. Miglioretti, M. Krapcho, A. Trentham-Dietz, D. Munoz, S.J. Lee, D.A. Berry, N.T. van Ravesteyn, O. Alagoz et al. (2016), “Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies,” Annals of Internal Medicine, 164(4):215-225.

26. M.J. Yaffe, N. Mittmann: Lee, A.T.A. Tosteson, A. Trentham-Dietz, O. Alagoz, N.K. Stout (2015), “Clinical outcomes of modelling mammography screening strategies,” Health Reports, 26(12):9-15.

27. N.T. van Ravesteyn, N.K. Stout, C.B. Schechter, E.A.M. Heijnsdijk, O. Alagoz, A. Trentham-Dietz, J.S. Mandelblatt, H.J. de Koning (2015), “Benefits and Harms of Mammography Screening after age 74 years: Model Estimates of Overdiagnosis,” Journal of the National Cancer Institute, 107(7):djv103.

28. B.L. Sprague, N.K. Stout, C. Schechter, N.T. van Ravesteyn, M. Cevik*, O. Alagoz, C.I. Lee, J.J. van den Broek, D.L. Miglioretti, J.S. Mandelblatt, H.J. de Koning, K. Kerlikowske, C.D. Lehman, A.N. A. Tosteson (2015), “Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts,” Annals of Internal Medicine, 162(3), 157-166.

29. N.K. Stout, S.J. Lee, C.B. Schechter, K. Kerlikowske, O. Alagoz, D. Berry, D.S.M. Buist, M. Cevik*, G. Chicholm, H.J. de Koning, H. Huang,  R.A. Hubbard, D.L. Miglioretti, M.F. Munsell, A. Trentham-Dietz, N.T. van Ravesteyn, A.N.A. Tosteson, J.S. Mandelblatt (2014), “Benefits, harms, and costs for breast cancer screening in the US following implementation of digital mammography,” Journal of the National Cancer Institute, 106(6): dju092.

30. D. Munoz, A.M. Near, N.T. van Ravesteyn, S.J. lee, C.B. Schechter, O. Alagoz, E. Burnside, D. Berry, Y. Chang, G. Chisholm, H.J. de Koning, M.A. Ergun*, E.A.M. Heijnsdijk, H. Huang, N.K. Stout, B. Sprague, A. Trentham-Dietz, J.S. Mandelblatt, S.K. Plevritis (2014), “Effects of Screening and Systemic Adjuvant Therapy on ER-Specific US Breast Cancer Mortality,” Journal of the National Cancer Institute, 106(11):dju289.

31. N.T. van Ravesteyn, D.L. Miglioretti, N.K. Stout, S.J. lee, C.B. Schechter, D.S.M. Buist, H. Huang, E.A.M. Heijnsdijk, A. Trentham-Dietz, O. Alagoz, A.M. Near, K. Kerlikowske, H.D. Nelson, J.S. Mandelblatt, H.J. de Koning (2012),"Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of risk," Annals of Internal Medicine, 156(9):609-17.